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Two types of interactions of 13 drugs with human fibroblasts were determined: (a) I,, of nuclear poly(ADP- 
ribose) polymerase, as assayed with isolated nuclei in vitro, and (b) the non-toxic concentration of drugs 
that prevented carcinogen-induced cell transformation of intact fibroblasts (RCF,). In general, RCF, was 
much lower than I,,, and one antitransformer did not inhibit the enzyme in vitro, indicating that low-affinity 
enzyme inhibitory sites appear to play no role in the mechanism of prevention of cell transformation. Two 
enzyme inhibitors, caffeine and I-methylnicotinamide, exhibited no antitransforming activity. Benzamide 
when applied in population doubling 1 induced resistance to cell transformation i population doubling 
6 by carcinogens added at this stage. 
Human fibroblast Ceil transformation Poly(ADP-ribose)polymerase 
1. INTRODUCTION 
An inhibitor of poly(ADP-ribose) polymerase, 
benzamide [11, when present at non-toxic concen- 
trations together with equally non-toxic quantities 
of ultimate carcinogens, prevents the induction of 
cell transformation in human fibroblasts that takes 
place in the absence of benzamide [2]. Similar 
observations were reported with C3HlOTM 
hamster embryo cells [3]. The antitransforming ac- 
tion of benzamide is confined to the early S phase 
and coincides with an increase of poly(ADP- 
ribose) polymerase activity [2], similar to the ap- 
parent induction of this enzyme in liver nuclei 
following benzamide feeding [4]. It would be ex- 
pected that the multi-stage process of cellular 
transformation, leading to neoplasia, might be ar- 
* To whom correspondence should be addressed 
rested by various agents at various stages (e.g., by 
prolonged exposure to protease inhibitors, cf. [5]) 
and the observed prevention of transformation by 
non-toxic concentrations of certain molecules that 
bind to the poly(ADP-ribose) polymerase system 
[2,3] is likely to indicate specific sites probably 
related to initiation. We show here that several in 
vitro inhibitors of poly(ADP-ribose) polymerase, 
at concentrations much below ISSO, can function as 
antitransformers in intact cells. Conversely, some 
agents known to prevent carcinogenesis n animals 
can also inhibit poly(ADP-ribose) polymerase in 
vitro at relatively high concentrations. Therefore, 
the antitransforming propensity of molecules can- 
not be fully correlated with an inhibition of 
poly(ADP-ribose) polymerase and the cell biologi- 
cal effect of antitransformers is more probably 
reflected in high-affinity nuclear binding sites 
(RCF, as compared to ISO). 
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2. EXPERIMENTAL 
Preparation, culturing, synchronization, the 
method of exposure of human fibroblasts to car- 
cinogens and to antitransforming drugs, and the 
assay technique for poly(ADP-ribose) polymerase, 
following quantitative removal of adsorbed drugs 
from the cell surface by both trypsin and anti- 
trypsin treatment, have been reported [2,7]. 
Ultimate carcinogens employed were methylazox- 
ymethanol acetate (MAMA, 7 ,KM) and N-methyl- 
N’-nitro-N-nitrosoguanidine (MNNG, 0.7 PM) 
which were used interchangeably because at these 
non-toxic doses their transforming effects were in- 
distinguishable. It is important to note that these 
low non-toxic concentrations of carcinogens are 
far below the doses many investigators use routine- 
ly in cell cultures to achieve responses in rates of 
poly ADP-ribosylations. For example, in a recent 
representative report MNNG was employed at 
nearly 50-times higher concentrations (cf. [8]) than 
in our studies. Toxicity, or rather its absence, was 
monitored by comparing cloning efficiencies in the 
presence and absence of drugs [2] and drug con- 
centrations defined as RCFr (where relative clon- 
ing frequency is equal to one, meaning that cloning 
efficiencies with and without drugs are identical) 
were used. This criterion, as illustrated in fig. 1 for 
benzamide, has been strictly employed for all 
drugs and drug combinations [2]. After exposure 
of cells in S of PDI (population doubling 1) to 
drugs, passages without drugs were continued for 
20 PD and transformation frequencies were then 
determined by colony counts of transformed cells 
after transfer of cultures to a soft (0.33%) agar 
medium, representing anchorage-independent 
growth [2,7]. The dose response between the con- 
centration of a typical antitransformer and the 
decrease in the number of colonies in soft agar 
(fig. 1) portrays a sensitive quantitative measure of 
inhibition of cell transformation. For comparison 
of many drugs (table 1) only one concentration of 
antitransformer drug (i.e., RCFi) is given, instead 
of a dose response curve which would involve 
almost unmanageable numbers of culture plates. 
For a total of 82 experimental series (table 1) bet- 
ween 1.6 and 2.0 x lo6 transformed colonies were 
counted (one colony = a minimum of 50 cells) and 
the average rate of transformation by carcinogens 
was between 40 and 50 colonies per lo4 cells [2]. 
Fig.1. Correlation between the concentration of 
extracellular applied benzamide (between 0 and 1 mM, 
abscissa) and the number of transformed cell colonies 
capable of growing in soft agar (expressed as number of 
colonies/100000 cells; ordinate of upper curve). The 
transforming agent was 7 PM methylazoxymethanol 
acetate. The lower curve indicates the absence of cellular 
toxicity of either 7 PM methylazoxymethanol acetate 
(not shown separately) and varying concentrations of 
benzamide alone or in combination with the carcinogen. 
Ordinate of lower curve is % cloning frequency; eight 
parallel experiments were performed according to [2]: 
error bars represent SD, n = 8. RCFr is by definition 
between 0.1 and 1 mM benzamide. 
Enzyme inhibitory indices (I&) and the nature of 
inhibition were determined, by standard kinetic 
models [9]. 
3. RESULTS AND DISCUSSION 
As summarized in table 1, 10 out of 13 
substances that at millimolar concentrations in- 
hibit in vitro the nuclear poly(ADP-ribose) 
polymerase system, as determined by initial veloci- 
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Table 1 
Prevention of carcinogen-induced cellular transformation of human fibroblasts by drugs that are inhibitory on 
poly(ADP-ribose) polymerase in vitro 
No. Experimental conditions No. of transformed 
colonies per 
5 x lo4 cells 
No. of 
experimental 
series 
150 (M) 
1 (4 
(b) 
(4 
2 (4 
w 
3 (a) 
(c) 
4 (a) 
(c) 
5 (a) 
(c) 
6 (a) 
(c) 
7 (a) 
(c) 
8 (a) 
(c) 
9 (a) 
(c) 
10 (a) 
(c) 
11 (a) 
(c) 
12 (a) 
(c) 
13 (a) 
(c) 
0.7 pM MNNG or 7 PM MAMA 
a. + 1 mM BA 
1 mM BA 
+ O.lmMBHA 
0.1 mM BHA 
+ 0.1 mM Me-BHA 
0.1 mM Me-BHA 
+ 0.7aM NAL 
0.1 PM NAL 
+ 0.8fiM NOV 
0.8/IM NOV 
+ 0.2pM LEV 
0.2/M LEV 
+ 69pM COU 
69 PM COU 
+ 3,uM QU 
3pM QU 
+ 0.4,~M IS0 
0.4pM IS0 
+ 1 mM l-Me-NA 
1 mM l-Me-NA 
+ 1 mM HMBA 
1 mM HMBA 
+ 1 mM CAFF 
1 mM CAFF 
0.8pM PRIM 
0.8 ,uM PRIM 
244.28 f 13.6 
0 
0 
1.4 +_ 0.6 
1.3 * 0.3 
1.0 + 0.4 
0 
2.0 + 1.5 
0 
8.0 + 2.3 
0 
6.0 + 1.8 
0 
1.0 -t 0.7 
13.0 f 4 
2.8 + 0.8 
27.0 f 3.3 
0 
0 
220.0 f 8.0 
2.0 f 1.3 
4.0 -t 1.3 
0 
210.0 + 15.0 
0 
4.0 + 1.5 
10.0 ~fr 8.0 
21 
2 
2 
2 
2 
3 
3 
2 
2 
2 
2 
5 
5 
5 
5 
2 
2 
2 
2 
2 
cf. [6] 
2 
2 
L 
not inhibitory 
at 20 mM 
2 
cf. [6] 
2 
2 
2 
0.5 x 1o-3 
5.0 x 1o-3 
20.0 x 1o-3 
2.0 x 1o-3 
10-s 
10-3 
10-3 
0.25 x 1O-3 
0.4 x lo-3 
2.0 x 1o-3 
BA, benzamide; BHA, butylated hydroxyanisole; Me-BHA, methyl ether of BHA; NAL, nalidixic acid; NOV, 
novobiocin; LEV, levimasole; COU, coumarin; QU, quercetin; ISO, isoquinoline; l-Me-NA, I-methylnicotinamide; 
HMBA, hexamethylene bisacetamide; CAFF, caffeine; PRIM, primycin. The cell biological effects of selected 
molecules were determined in synchronized human fibroblasts exactly as in [2]. Briefly, GI block was produced in 
freshly isolated and subcultured human fibroblasts (5 x lo3 cell/cm*) by nutritional deprivation (cf. [2]) then S induced 
by refeeding + insulin. Transforming agents and drugs were added in early S phase. The window of effectivity of both 
agents was the same as described (cf. [2]). Passages for 20 population doubling were continued and treated and control 
cultures seeded (3-20 x lo6 cells) into a semi-solid medium (0.33% agar, cf. [2]) to score for anchorage-independent 
colony growth (1 colony is defined as a minimum of 50 cells). The drug concentrations given in section 2 are RCFI (i.e., 
a non-toxic dose that inhibits transformation by 85-95%) 
ty enzyme kinetics [9], proved to be potent an- 
titransforming drugs. With the apparent exception 
of benzamide the concentrations of drugs suffi- 
cient to prevent nearly completely transformation 
are far below ISO. The anomalous behavior of ben- 
zamide is explained by its poor cellular penetration 
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(less than 1% of externally added drug appears in 
the nucleus, cf. [2]). Caffeine (no.12) and 
I-methylnicotinamide (no.10) which are known in- 
hibitors of the enzyme (cf. [6]) do not act as an- 
titransformers, therefore in vitro kinetic effects 
alone are insufficient to predict an antitransform- 
ing property. The process leading to transforma- 
tion inhibition takes about 10 h [2] whereas inhibi- 
tion kinetics is determined within l-2 min. It 
follows that differences in drug concentrations 
that cause enzyme inhibition or prevention of 
transformation suggest he participation of at least 
two types of binding sites and only the high- 
affinity site (RCF,) is relevant o the prevention of 
transformation. Recent evidence shows the par- 
ticipation of a second nuclear binding site for ben- 
zamide which is localized at the coenzymic DNA of 
poly(ADP-ribose) polymerase (in preparation; and 
Proceedings of the VIIth International Symposium 
on ADP-ribosylations, Vitznau, Switzerland, Sept. 
23-27, 1984) and we presume that other an- 
titransformers also bind to this site. This question 
is the subject of further studies. 
Benzamide (no. 1) and its ortho- and meta-fluoro 
analogs, m-methoxybenzamide and the 2-(aceto- 
nyloxy),-2-(phenylacetonyloxy)-5chlorobenza- 
mides (not shown) are comparable antitransfor- 
mers. Benzamides are toxic at 5 mM, except for 
the acetonyloxychloro derivatives which are non- 
toxic even at saturation. Butylated hydroxyanisole 
(no.2), a known inhibitor of carcinogenesis in 
animals [lo] and its o-methyl derivative (no.3), 
prevent transformation in the cell culture system. 
The antibiotics, nalidixic acid (no.4) and novobio- 
tin (no.S), at millimolar concentration, exert an 
inhibitory effect on eukaryotic topoisomerases 
[ 13,141 as well as on poly(ADP-ribose) polymerase 
(table l), suggesting DNA-related binding sites. 
However, the antitransforming effect of these anti- 
biotics (nos 4,5) and of the antibiotic primycin 
(no.13) occurs at much lower concentration than 
ZSO, similar to levimasole, a drug (no.6) that is 
known to be supportive in cancer chemotherapy 
[ 11,121, The bioflavonoid derivatives quercetin 
and coumarin (nos 7,8) are potent antitransfor- 
mers at 3 and 69pM, respectively. Quercetin has 
been shown to suppress tumor promotion [15] and 
contrary to previous reports is not a carcinogen 
[ 161, thus the marginal induction of transformed 
colonies by quercetin alone, that is abolished by 
the simultaneous presence of a potent carcinogen, 
may have little biological importance. The inhibi- 
tory effect of quercetin on tyrosine phosphokinase 
[17] and on other enzymes of the plasma mem- 
brane [ 181 requires 50- 1 00-fold higher concentra- 
tions than sufficient for the prevention of car- 
cinogen-induced phenotypic transformation (table 
1, nos 7,8). Therefore, it seems improbable that 
these enzymes are significantly affected by quer- 
cetin when prevention of cell transformation takes 
place. Isoquinoline (no.9) bears structural homo- 
logy to benzamide with respect to the position of 
the N atom relative to the benzene moiety. 
Hexamethylene bisacetamide (no. 11) is known 
to induce differentiation in erythroleukemia cells 
[ 191 simultaneously with an increase of poly(ADP- 
ribose) polymerase activity [20]. Its antitransform- 
ing effect in human fibroblasts suggests that the 
phenomenon of induced differentiation [ 191 and of 
induced resistance to transformation, both coin- 
ciding with an increase of poly ADP-ribosylation, 
may be related. Hexamethylene bisacetamide at 
1 mM external concentration (RCF,) almost com- 
pletely prevented carcinogen-induced transforma- 
tion, but even at 20 mM had no appreciable in- 
hibitory effect on nuclear poly(ADP-ribose) 
polymerase. In the past [2] and in the majority of 
present experiments, prevention of transformation 
was demonstrated when both carcinogens and an- 
titransforming drugs were present simultaneously 
Table 2 
Induction of resistance to cell transformation by 
benzamide 
No. Experimental conditions No.of transformed 
colonies per lo5 
cells after PD2e 
1 PDr 0.7/M MNNG alone 185 k 18 (2)a 
2 l.+lmMBA 5 + 2 (2) 
3 1 mM BA alone 0 (2) 
4 1 mM BA at PDr and 0.7pM 
MNNG at PDs 0 (2) 
5 0.1 PM MNNG alone at PDs 130 f 18 (2) 
PDI and PDa, population doubling 1 and 6, respectively; 
(2)=, 2 experimental series; the cells used in these 
experiments exhibited greater resistance than the 
cultures shown in table 1, indicating biological 
variations. BA, benzamide 
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in early S phase. However, one exposure to ben- 
zamide alone at PDr confers resistance to transfor- 
mation as demonstrated by the ineffectivity of the 
subsequent addition of carcinogens at PDh, when 
traces of benzamide have long been removed by 6 
serial passages involving exchanges of culture 
media (table 2). It is probable that benzamide is 
not unique in producing resistance to transforma- 
tion. The mechanism of this phenomenon is sub- 
ject to further studies. The antitransforming effect 
of certain drugs (table 1) depends strictly on their 
low concentration that must be at non-toxic levels. 
Raising the drug concentration to IS,-, will not only 
abolish the antitransforming effect but also pro- 
duce cell toxicity and can reinforce carcinogens 
(cf. L4h 
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